Drug Profile
Research programme: beta-lactamase stimulants - Theriva Biologics
Alternative Names: P1B; P1C; P2A; P2B; P2C; P4A; SYN-006 - Theriva BiologicsLatest Information Update: 14 Oct 2022
Price :
$50
*
At a glance
- Originator Ipsat Therapies
- Developer Theriva Biologics
- Class Enzymes
- Mechanism of Action Beta lactamase stimulants; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Clostridium difficile infections; Diarrhoea
Most Recent Events
- 12 Oct 2022 Synthetic Biologics is now called Theriva Biologics
- 28 Apr 2021 No recent reports of development identified for research development in Diarrhoea in USA (PO)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Clostridium-difficile-infections(Prevention) in USA (PO, Capsule)